



- (51) **International Patent Classification:**
C07K 16/28 (2006.01) *A61P 1/08* (2006.01)
- (21) **International Application Number:**
PCT/US2024/040113
- (22) **International Filing Date:**
30 July 2024 (30.07.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/516,724 31 July 2023 (31.07.2023) US
- (71) **Applicant: NGM BIOPHARMACEUTICALS, INC.**
[US/US]; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US).
- (72) **Inventors: DEPAOLI, Alexander M.**; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **HENSCHEL, Carroll E.**; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **HSU, Jer-Yuan**; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US). **JEFFRY, Ursula B.**; 333 Oyster Point Boulevard, South San Francisco, California 94080 (US).
- (74) **Agent: KOIPALLY, Joseph J.** et al.; Fish & Richardson, P.O. Box 1022, Minneapolis, Minnesota 55440-1022 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
- (84) **Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,

(54) **Title:** METHODS OF TREATING NAUSEA AND VOMITING DISORDERS USING ANTI-GFRAL ANTIBODIES




FIG. 14

(57) **Abstract:** The present disclosure relates generally to methods of treating, preventing, or reducing nausea, vomiting, or a combination thereof, hyperemesis gravidarum (HG), nausea and vomiting of pregnancy (NVP), or sequelae thereof in a human subject in need thereof, the method comprising administering to the human subject a therapeutically effective amount of an antibody that specifically binds to human glial cell line-derived neurotrophic factor family receptor alpha-like (GFRAL).

[Continued on next page]

SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *with sequence listing part of description (Rule 5.2(a))*